Pricing

Top 25 rare disease brands, by sales

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

By

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Five things for pharma marketers to know: Monday, February 6, 2017

Five things for pharma marketers to know: Monday, February 6, 2017

By

Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year

It's Time for Trump to Make Good on his Drug Pricing Promises

It's Time for Trump to Make Good on his Drug Pricing Promises

Last week President Trump told drugmakers that 'the pricing has been astronomical.'

MM&M's top 5 stories in January 2017

MM&M's top 5 stories in January 2017

By

Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

Pharma/Payer Collaboration: A Kumbaya Moment or a Passing Trend?

By

The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.

Five things for pharma marketers to know: Tuesday, January 31, 2017

Five things for pharma marketers to know: Tuesday, January 31, 2017

By

Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing

Five things for pharma marketers to know: Monday, January 30, 2017

Five things for pharma marketers to know: Monday, January 30, 2017

By

Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

By

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Infographic: What payers want from pharma

Infographic: What payers want from pharma

One pharmacy director would like to see a lot more comparative data about new therapies.

Five things for pharma marketers to know: Tuesday, January 24, 2017

Five things for pharma marketers to know: Tuesday, January 24, 2017

By

Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role

Five things for pharma marketers to know: Thursday, January 12, 2017

Five things for pharma marketers to know: Thursday, January 12, 2017

By

Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

By

J&J's CEO may be right. Customers of all kinds are demanding change.

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

By

The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.

MM&M staff predictions: From drug pricing to big data

MM&M staff predictions: From drug pricing to big data

By

Our editorial staff contemplates what 2017 has in store for healthcare marketers, and we forsee big changes and some setbacks in the ongoing shift toward a data-driven, value-based industry.

Five things for pharma marketers to know: Tuesday, December 27, 2016

Five things for pharma marketers to know: Tuesday, December 27, 2016

By

Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug

Five things for pharma marketers to know: Thursday, December 15, 2016

Five things for pharma marketers to know: Thursday, December 15, 2016

By

Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares

Eli Lilly will discount its insulins to some patients

Eli Lilly will discount its insulins to some patients

By

Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.

Five things for pharma marketers to know: Thursday, December 8, 2016

Five things for pharma marketers to know: Thursday, December 8, 2016

By

A California lawmaker reintroduces drug-pricing bill; France, Poland, Spain, and Sweden lobby to host EMA; drug stocks fall after Trump's comments

Five things for pharma marketers to know: Wednesday, December 7, 2016

Five things for pharma marketers to know: Wednesday, December 7, 2016

By

Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine

Five things for pharma marketers to know: Tuesday, December 6, 2016

Five things for pharma marketers to know: Tuesday, December 6, 2016

By

Prices of Viagra and Cialis triple since 2010; AstraZeneca's Tagrisso slows lung-cancer progression compared to chemo; Novo Nordisk to limit price increases

Five things for pharma marketers to know: Friday, December 2, 2016

Five things for pharma marketers to know: Friday, December 2, 2016

By

Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

By

Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.

Five things for pharma marketers to know: Thursday, December 1, 2016

Five things for pharma marketers to know: Thursday, December 1, 2016

By

Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election

The New Reality for Pharma Marketers is Drug Pricing

The New Reality for Pharma Marketers is Drug Pricing

By

My hope is that all of us do a better job of focusing on value.

Five things for pharma marketers to know: Wednesday, November 16, 2016

Five things for pharma marketers to know: Wednesday, November 16, 2016

By

The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Five things for pharma marketers to know: Thursday, November 10, 2016

Five things for pharma marketers to know: Thursday, November 10, 2016

By

Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

By

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

OPINION

Email Newsletters